Coria Acquisition Expands Valeant Pharmaceuticals’ Dermatology Holdings
This article was originally published in The Rose Sheet
Executive Summary
Valient Pharmaceuticals International will grow its U.S. dermatology franchise through an acquisition of Coria Laboratories from DFB Pharmaceuticals, the firm announces Sept. 17